Drugs / Yuxi Walvax MPV ACYW
Yuxi Walvax MPV ACYW
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04450498 | Dec 2020 → Jul 2021 | meningococcal meningitis | Walvax Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yuxi Walvax MPV ACYW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450498 ↗ |
| Known as | MPV ACYW135 | “A phase IV randomized, observer-blind, controlled study compared the safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV-4, MPV ACYW135) and...” PMID 37401618 ↗ Jul 2023 |
| Known as | MPV-4 | “A phase IV randomized, observer-blind, controlled study compared the safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV-4, MPV ACYW135) and...” PMID 37401618 ↗ Jul 2023 |
| Known as | Walvax MPV ACYW vaccine | “Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135.” NCT04450498 ↗ |
| Modality | Vaccine | “quadrivalent meningococcal polysaccharide vaccine (MPV-4, MPV ACYW135)” PMID 37401618 ↗ Jul 2023 |
| Route | Subcutaneous | “After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection.” NCT04450498 ↗ |